Philip He

6PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 01, 2026
Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

|May 11, 2025
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.

Philip He, Dhiraj Gambhire, Haiming Zhou

|Dec 28, 2024
A Bayesian Hybrid Design With Borrowing From Historical Study.

Zhaohua Lu, John Toso, Girma Ayele

|Feb 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Sophie Wildsmith, Weimin Li, Song Wu

|Dec 08, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.

Xuyang Song, Robin Kate Kelley, Anis A Khan

|Jul 22, 2021
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.

Robin Kate Kelley, Bruno Sangro, William Harris

Pageof 1

Frequent Collaborators

2 joint publications

Robin Kate Kelley

2 joint publications

Ghassan K Abou-Alfa

1 joint publications

Masafumi Ikeda

1 joint publications

Takuji Okusaka